目的:在四氯化碳(CCl4)诱导的肝损伤中,但在药物诱导的肝损伤(DILI)情况下,已经探索了东铂乙素的肝保护特性。只有N-乙酰-半胱氨酸(NAC)在DILI治疗中被证明有效。因此,我们进行了一项研究,以评估在抗结核治疗(ATT)-DILI模型中,在Wistar大鼠的肝保护作用,如果有的话。
方法:对36只大鼠进行评估,每组6人。对于异烟肼,以100mg/kg的剂量进行36天的ATT,饲喂利福平300mg/kg和吡嗪酰胺700mg/kg以诱导大鼠的肝毒性。I组和II-VI组接受生理盐水和ATT,分别。第三组口服替罗素(1,5和10mg/kg)和NAC150mg/kg,IV,V和VI,分别,在实验的最后15天每天一次。LFT监测在基线进行,第21、28和36天。处死大鼠进行组织病理学检查。
结果:天冬氨酸转氨酶(AST),丙氨酸转氨酶(ALT),在第28天和第36天,与正常对照组相比,II组(接受ATT)的碱性磷酸酶(ALP)和胆红素水平显着升高(p<0.05)。所有三个剂量的sopoletin和NAC组均导致AST的消退,ALT,ALP,由ATT药物诱导的胆红素变化从第28天开始并持续到第36天(p<0.01)。观察到对白蛋白和总蛋白水平的影响不显著。抗氧化剂和组织病理学分析证实了该作用。
结论:该研究证实了在更强大的常见肝损伤病因中,司波利坦的肝保护功效。
OBJECTIVE: The hepatoprotective properties of scopoletin have been explored in carbon tetrachloride (CCl4) induced liver injury but not in drug-induced liver injury (DILI) scenarios. Only N-acetyl-cysteine (NAC) has proven efficacy in DILI treatment. Accordingly, we conducted a study to assess the hepatoprotective action of scopoletin in the anti-tubercular treatment (ATT)-DILI model in Wistar rats, if any.
METHODS: A total of 36 rats were evaluated, with six in each group. A 36-day ATT at 100 mg/kg dose for isoniazid, 300 mg/kg for rifampicin and 700 mg/kg for pyrazinamide were fed to induce hepatotoxicity in rats. Group I and II-VI received normal saline and ATT, respectively. Oral scopoletin (1,5 and 10 mg/kg) and NAC 150 mg/kg were administered in groups III, IV, V and VI, respectively, once daily for the last 15 days of the experiment. LFT monitoring was performed at baseline, days 21, 28, and 36. Rats were sacrificed for the histopathology examination.
RESULTS: Aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and bilirubin levels were significantly increased in group II (receiving ATT) compared to normal control on day 28 and day 36 (p<0.05). All three doses of scopoletin and NAC groups led to the resolution of AST, ALT, ALP, and bilirubin changes induced by ATT medications effect beginning by day 28 and persisting on day 36 (p<0.01). An insignificant effect was observed on albumin and total protein levels. The effect was confirmed with antioxidants and histopathology analysis.
CONCLUSIONS: The study confirms the hepatoprotective efficacy of scopoletin in a more robust commonly encountered liver injury etiology.